US8685934 — Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
Method of Use · Assigned to Bristol Myers Squibb Co · Expires 2030-05-26 · 4y remaining
What this patent protects
This patent protects methods for treating type 2 diabetes in patients who have not responded to other treatments, using an SGLT2 inhibitor, such as dapagliflozin, alone or in combination with other medications.
USPTO Abstract
The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.
Drugs covered by this patent
- Farxiga (DAPAGLIFLOZIN) · AstraZeneca
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1522 |
— | Farxiga |
U-1522 |
— | Farxiga |
U-1522 |
— | Farxiga |
U-1522 |
— | Farxiga |
U-1522 |
— | Farxiga |
U-1522 |
— | Farxiga |
U-1522 |
— | Farxiga |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.